Podcast appearances and mentions of Bruce R Korf

  • 12PODCASTS
  • 24EPISODES
  • 1h 10mAVG DURATION
  • ?INFREQUENT EPISODES
  • Jun 16, 2022LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Bruce R Korf

Latest podcast episodes about Bruce R Korf

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 16, 2022 60:11


Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion of this activity, participants should be better able to: Summarize the genetic etiology, diverse clinical symptomatology, and diagnostic criteria of neurofibromatosis type 1 (NF1), Cite the current evidence from pivotal clinical trials on MEK inhibitors and other targeted therapies for the treatment of NF1-related PNs and other tumors in pediatric populations, Select personalized treatment plans using MEK inhibitors and other targeted therapies in pediatric populations with NF1-related plexiform neurofibromas (PNs) and other tumors based on prognostic information, safety considerations, and the latest evidence and guideline recommendations, Develop a management plan for the unique spectrum of adverse events associated with novel therapeutics including MEK inhibitors in pediatric patients with NF1-associated tumors.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 16, 2022 60:14


Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion of this activity, participants should be better able to: Summarize the genetic etiology, diverse clinical symptomatology, and diagnostic criteria of neurofibromatosis type 1 (NF1), Cite the current evidence from pivotal clinical trials on MEK inhibitors and other targeted therapies for the treatment of NF1-related PNs and other tumors in pediatric populations, Select personalized treatment plans using MEK inhibitors and other targeted therapies in pediatric populations with NF1-related plexiform neurofibromas (PNs) and other tumors based on prognostic information, safety considerations, and the latest evidence and guideline recommendations, Develop a management plan for the unique spectrum of adverse events associated with novel therapeutics including MEK inhibitors in pediatric patients with NF1-associated tumors.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 16, 2022 60:11


Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion of this activity, participants should be better able to: Summarize the genetic etiology, diverse clinical symptomatology, and diagnostic criteria of neurofibromatosis type 1 (NF1), Cite the current evidence from pivotal clinical trials on MEK inhibitors and other targeted therapies for the treatment of NF1-related PNs and other tumors in pediatric populations, Select personalized treatment plans using MEK inhibitors and other targeted therapies in pediatric populations with NF1-related plexiform neurofibromas (PNs) and other tumors based on prognostic information, safety considerations, and the latest evidence and guideline recommendations, Develop a management plan for the unique spectrum of adverse events associated with novel therapeutics including MEK inhibitors in pediatric patients with NF1-associated tumors.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 16, 2022 60:14


Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion of this activity, participants should be better able to: Summarize the genetic etiology, diverse clinical symptomatology, and diagnostic criteria of neurofibromatosis type 1 (NF1), Cite the current evidence from pivotal clinical trials on MEK inhibitors and other targeted therapies for the treatment of NF1-related PNs and other tumors in pediatric populations, Select personalized treatment plans using MEK inhibitors and other targeted therapies in pediatric populations with NF1-related plexiform neurofibromas (PNs) and other tumors based on prognostic information, safety considerations, and the latest evidence and guideline recommendations, Develop a management plan for the unique spectrum of adverse events associated with novel therapeutics including MEK inhibitors in pediatric patients with NF1-associated tumors.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 16, 2022 60:14


Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion of this activity, participants should be better able to: Summarize the genetic etiology, diverse clinical symptomatology, and diagnostic criteria of neurofibromatosis type 1 (NF1), Cite the current evidence from pivotal clinical trials on MEK inhibitors and other targeted therapies for the treatment of NF1-related PNs and other tumors in pediatric populations, Select personalized treatment plans using MEK inhibitors and other targeted therapies in pediatric populations with NF1-related plexiform neurofibromas (PNs) and other tumors based on prognostic information, safety considerations, and the latest evidence and guideline recommendations, Develop a management plan for the unique spectrum of adverse events associated with novel therapeutics including MEK inhibitors in pediatric patients with NF1-associated tumors.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jun 16, 2022 60:11


Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion of this activity, participants should be better able to: Summarize the genetic etiology, diverse clinical symptomatology, and diagnostic criteria of neurofibromatosis type 1 (NF1), Cite the current evidence from pivotal clinical trials on MEK inhibitors and other targeted therapies for the treatment of NF1-related PNs and other tumors in pediatric populations, Select personalized treatment plans using MEK inhibitors and other targeted therapies in pediatric populations with NF1-related plexiform neurofibromas (PNs) and other tumors based on prognostic information, safety considerations, and the latest evidence and guideline recommendations, Develop a management plan for the unique spectrum of adverse events associated with novel therapeutics including MEK inhibitors in pediatric patients with NF1-associated tumors.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 26, 2021 60:16


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 26, 2021 60:16


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 60:04


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 60:04


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 26, 2021 60:16


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 60:04


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 26, 2021 60:16


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 60:04


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 26, 2021 60:16


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 26, 2021 60:04


Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 8, 2021 91:21


Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 8, 2021 90:49


Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 8, 2021 90:49


Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 8, 2021 90:49


Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 8, 2021 91:21


Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 8, 2021 91:21


Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 8, 2021 90:49


Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 8, 2021 91:21


Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.